Pfizer receives FDA breakthrough therapy designation for XALKORI® (crizotinib)
Pfizer announced that XALKORI® (crizotinib) received Breakthrough Therapy designation by the FDA for potential treatment of patients with ROS1-positive non-small cell lung cancer. XALKORI currently is approved in the U.S. for the treatment of patients with metastatic NSCLC. April 21, 2015